Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 30.12% is in line with its 5-year average of 32.60%, near the low end of its 5-year range (25.60%–40.74%).
0.82% below its 12-month average of 30.37%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 30.52%.
GROSS MARGIN
30.12%
GROSS MARGIN AVG TTM
30.37%
GROSS MARGIN AVG 3Y
32.76%
GROSS MARGIN AVG 5Y
32.60%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.82%
CURRENT VS 3Y AVG
-8.06%
CURRENT VS 5Y AVG
-7.61%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-27.21%
vs the sector median at left
Market Cap
$35.84M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
22.09%
Market Cap
$35.52M
Gross Margin
39.56%
TTM Avg
49.73%
3Y Avg
-33.76%
5Y Avg
-21.28%
Market Cap
$36.19M
Gross Margin
41.73%
TTM Avg
31.44%
3Y Avg
27.18%
5Y Avg
29.99%
Market Cap
$34.97M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$37.57M
Gross Margin
0.00%
TTM Avg
-93.03%
3Y Avg
-21.51%
5Y Avg
10.85%
Market Cap
$33.63M
Gross Margin
49.68%
TTM Avg
60.09%
3Y Avg
64.56%
5Y Avg
72.92%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| DocGo Inc. (DCGO) | $35.76M | 30.12% | 30.37% | 32.76% | 32.60% |
| Edesa Biotech, Inc. (EDSA)vs › | $35.84M | 0.00% | 0.00% | 0.00% | 15.78% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $35.84M | 0.00% | 0.00% | 0.00% | 22.09% |
| QT Imaging Holdings, Inc. (QTI)vs › | $35.52M | 39.56% | 49.73% | -33.76% | -21.28% |
| EUDA Health Holdings Limited (EUDA)vs › | $36.19M | 41.73% | 31.44% | 27.18% | 29.99% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $34.97M | 0.00% | 0.00% | 0.00% | 0.00% |
| Elutia Inc (ELUT)vs › | $34.23M | 57.82% | 48.80% | 47.77% | 46.56% |
| Incannex Healthcare Limited (IXHL)vs › | $37.57M | 0.00% | -93.03% | -21.51% | 10.85% |
| Scilex Holding Company (SCLX)vs › | $33.63M | 49.68% | 60.09% | 64.56% | 72.92% |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.61M | 0.00% | 0.00% | 0.00% | 10.20% |
Gross Margin
30.1%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 30.52% |
| 2026-03-31 | 31.61% |
| 2025-12-31 | 32.51% |
| 2025-09-30 | 25.60% |
| 2025-06-30 | 31.61% |
| 2025-03-31 | 32.12% |
| 2024-12-31 | 33.52% |
| 2024-09-30 | 36.00% |
| 2024-06-30 | 33.88% |
| 2024-03-31 | 35.02% |
| 2023-12-31 | 33.47% |
| 2023-09-30 | 29.51% |
| 2023-06-30 | 33.37% |
| 2023-03-31 | 28.12% |
| 2022-12-31 | 38.98% |
| 2022-09-30 | 31.70% |
| 2022-06-30 | 35.92% |
| 2022-03-31 | 33.85% |
| 2021-12-31 | 40.74% |
| 2021-09-30 | 30.07% |
| 2021-06-30 | 34.03% |
| 2021-03-31 | 27.83% |
| 2020-12-31 | 33.44% |
| 2020-09-30 | 32.20% |
| 2020-06-30 | 38.08% |
| 2020-03-31 | 27.26% |
